5 pending office actions • 2 clients
| Client (Assignee) | Pending OAs |
|---|---|
| Alnylam Pharmaceuticals, Inc. | 4 |
| Alnylam Pharmaceuticals, Inc. | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 19079175 | Untitled | Alnylam Pharmaceuticals, Inc. | HUDSON, AMY ROSE | 1636 | Non-Final OA | |
| 18259887 | 2'-MODIFIED NUCLEOSIDE BASED OLIGONUCLEOTIDE PRODRUGS | Alnylam Pharmaceuticals, Inc. | BRETZ, COREY LANE | 1635 | Non-Final OA | Jun 29, 2023 |
| 18015202 | Circular siRNAs | Alnylam Pharmaceuticals, Inc. | TRAN, CHRISTINA L | 1637 | Non-Final OA | Jan 09, 2023 |
| 17982819 | CHIRALLY-ENRICHED DOUBLE-STRANDED RNA AGENTS | Alnylam Pharmaceuticals, Inc. | ANGELL, JON E | 1637 | Non-Final OA | Nov 08, 2022 |
| 17774477 | EXTRAHEPATIC DELIVERY | Alnylam Pharmaceuticals, Inc. | VANHORN, ABIGAIL LOUISE | 1636 | Final Rejection | May 04, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial